What's New in Heart Failure Treatment? FDA-Approved Drugs to Know

Heart failure treatment has changed significantly in recent years, with several FDA-approved drugs now available for different types of the condition. These medications can help reduce symptoms, lower hospitalization risk, and improve survival for many patients. Understanding how the latest options work, who they may help, and what they cost can make conversations with a healthcare professional more productive.

What's New in Heart Failure Treatment? FDA-Approved Drugs to Know

Heart failure is a long-term condition in which the heart cannot pump enough blood to meet the body’s needs. It does not mean the heart has stopped. Instead, the heart may be too weak or too stiff to fill and eject blood efficiently. Treatment usually combines lifestyle changes, device therapy in some cases, and medications that target different pathways involved in heart failure. Recent drug approvals have expanded the options for patients with reduced and preserved ejection fraction, offering new ways to manage symptoms and slow progression.

What Are the Latest FDA-Approved Drugs for Heart Failure?

Several drugs have received FDA approval for heart failure in recent years. Sacubitril/valsartan (Entresto) is an angiotensin receptor-neprilysin inhibitor approved for heart failure with reduced ejection fraction and some patients with preserved ejection fraction. SGLT2 inhibitors, including empagliflozin (Jardiance) and dapagliflozin (Farxiga), were initially developed for diabetes but are now approved for heart failure across a range of ejection fractions. Ivabradine (Corlanor) is approved for certain patients with stable heart failure with reduced ejection fraction and elevated heart rate. Vericiguat (Verquvo) is approved for chronic heart failure with reduced ejection fraction after worsening symptoms. Finerenone (Kerendia) is another option that has been studied and approved for certain patients with heart failure and chronic kidney disease associated with type 2 diabetes. These approvals reflect a shift toward treating heart failure as a condition with multiple underlying mechanisms.

How Do New Heart Failure Medications Work?

Newer heart failure drugs act on different parts of the cardiovascular and metabolic systems. ARNIs, such as sacubitril/valsartan, combine an angiotensin receptor blocker with a neprilysin inhibitor. This dual action relaxes blood vessels, reduces sodium retention, and decreases the strain on the heart. SGLT2 inhibitors lower glucose reabsorption in the kidneys, but they also promote sodium and water excretion, reduce preload and afterload, and may improve cardiac energy use. Ivabradine slows the heart rate by inhibiting the If current in the sinoatrial node, which can help the heart fill more effectively. Vericiguat stimulates soluble guanylate cyclase, leading to smooth muscle relaxation and reduced vascular resistance. Finerenone blocks mineralocorticoid receptors, which can reduce inflammation and fibrosis in the heart and kidneys. Because these drugs target distinct pathways, they are often used together rather than as alternatives.

Comparing Heart Failure Treatments: Benefits, Risks, Costs

When comparing heart failure treatments, benefits, risks, and costs all matter. Benefits may include fewer symptoms, reduced hospitalizations, and improved survival, but the exact effect depends on the drug, the patient’s ejection fraction, kidney function, blood pressure, and other conditions. Common risks include low blood pressure, dizziness, kidney function changes, high potassium, and dehydration. SGLT2 inhibitors can increase the risk of genital fungal infections and, rarely, diabetic ketoacidosis. Ivabradine may cause bradycardia or visual disturbances. ARNIs can cause angioedema, though this is uncommon. Costs vary widely. Generic beta blockers, ACE inhibitors, and mineralocorticoid receptor antagonists are often inexpensive, while brand-name ARNIs, SGLT2 inhibitors, ivabradine, and vericiguat can have high retail prices without insurance. Medicare, Medicaid, commercial insurance, manufacturer assistance programs, and foundation grants may reduce out-of-pocket expenses.

In real-world practice, monthly out-of-pocket costs depend on insurance coverage, deductibles, pharmacy choice, and whether a generic is available. The estimates below reflect typical U.S. retail prices before insurance or assistance and are not a promise of what any individual will pay. Generic drugs are generally much less expensive than brand-name options, but not every patient can switch because of medical history, tolerability, or formulary rules.


Product/Service Provider Cost Estimation
Entresto (sacubitril/valsartan) Novartis $600–$700 per month retail
Jardiance (empagliflozin) Boehringer Ingelheim and Eli Lilly $600–$700 per month retail
Farxiga (dapagliflozin) AstraZeneca $600–$700 per month retail
Corlanor (ivabradine) Amgen $400–$500 per month retail
Verquvo (vericiguat) Merck $600–$700 per month retail
Carvedilol (generic) Multiple manufacturers $10–$30 per month
Spironolactone (generic) Multiple manufacturers $10–$30 per month

Prices, rates, or cost estimates mentioned in this article are based on the latest available information but may change over time. Independent research is advised before making financial decisions.

Heart failure treatment continues to evolve, and the range of FDA-approved drugs now reflects a deeper understanding of the condition’s different forms. Patients who discuss newer options with a cardiologist or primary care clinician can learn whether a medication is appropriate for their ejection fraction, kidney function, and overall health. Because heart failure care is highly individual, the most useful plan is one built around a person’s specific risks, benefits, and financial situation.

This article is for informational purposes only and should not be considered medical advice. Please consult a qualified healthcare professional for personalized guidance and treatment.